The Continued Buzz Surrounding Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO) | Financial Buzz

The Continued Buzz Surrounding Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO)

Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace.

About:

 

Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug-screening devices that will detect THC- the psychoactive component of marijuana that causes impairment using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment.

Our Behind the Buzz Show Featuring
Cannabix Technologies Inc.

Our Buzz on the Street Show Featuring
Cannabix Technologies Inc.

Investor Recap

Technology

Cannabix Thc Breath Analyzer (Thcba)

The THC Breath Analyzer (THCBA),is a point of care breath testing tool for the rapid detection of recent  cannabis use (within 1-3 hours). The underlying technology for the THCBA uses microfluidic sensors coupled with machine learning algorithms which operates under principles similar to mammalian olfaction systems.

Microfluidic-based artificial olfaction technology pairs gas sensors, such as metal oxide semiconductor, with microfluidic channels for detection of THC in breath samples. The THCBA collects a single breath from the user and the sensor response is represented by a characteristic pattern or “smell-print” to the specific target gas.

The Cannabix THCBA device is at the advanced prototype stage.

Faims Thc Breathalyzer System

There are thousands of different molecules present in human breath, and those associated with recent cannabis use are often far from the most abundant compounds present, especially when other compounds, such as nicotine, are also consumed.  Please also see why breath correlates better with the peak THC impairment window. The Cannabix FAIMS device is designed to operate both independently or coupled in tandem directly to a mass spectrometer (MS), used in forensic labs.

Image of FAIMS device under development

MS is considered the gold standard in toxicology for the analysis of drugs, poisons, and metabolites, due to its superior specificity and sensitivity. The highly selective Cannabix FAIMS device can potentially be employed in many related applications, either at the point of care or in the laboratory.  The Cannabix FAIMS device is used in combination with the Breath Collection Unit. The Cannabix FAIMS device is at the advanced prototype stage.

Recent Developments

May 4 - Cannabix Technologies Receives Notice of Allowance for Detection of Molecules - FAIMS U.S. Patent

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company” or “Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application, No. 17/019728 entitled, “Apparatus and Methods for Detection of Molecules”. This Track 1 patent application is centered on innovations made by Cannabix with its FAIMS (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer technology. This patent application is the culmination of research and development work conducted by Cannabix scientists and engineers in the areas of ion mobility spectrometry, non-volatile molecule sampling and fluid dynamics. These developments will provide utility in several areas related to detection of molecules in breath.

Cannabix is using its FAIMS technology to isolate and detect ∆9-tetrahydrocannabinol (“THC”), a non-volatile compound, in breath. The Cannabix FAIMS marijuana breathalyzer device uses ion mobility filtering techniques (related to mass spectrometry – the gold standard analytical technique for molecular detection). The Cannabix device has been designed and built in a series of modules that together allow for sample intake, ionization, filtering and detection – all done under atmospheric pressure. In addition, the device has the ability to couple directly to a mass spectrometer in order to validate its detector responses.

 

It should be noted that a notice of allowance from the USPTO does not constitute a grant of patent. The Company will report on future material developments regarding its “Apparatus and Methods for Detection of Molecules” patent application in due course.

The Company has been steadily growing its intellectual property (IP) portfolio over recent months. In April, the Company received a notice of allowance for its patent application, No. 2887841 entitled, “Cannabis Drug Detection Device” from the Canadian Intellectual Property Office (CIPO). In addition, the Company was granted a granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” from the USPTO in January 2021. The newly received notice of allowance from the USPTO for its FAIMS related patent application builds on this IP momentum.

The Company expects to ship its THCBA to a clinic in the Northwestern, U.S. for beta testing in May. The collaborating clinic has a robust drug testing operation and is one of the top drug testing providers to employers within its respective state. The beta testing is focussed on improving user experience through testing and feedback and training the device’s machine learning database.

For Full Release: https://finance.yahoo.com/news/cannabix-technologies-receives-notice-allowance-124500561.html

April 19, 2021 - Cannabix Technologies Receives Notice of Allowance for Cannabis Drug Detection Device Canadian Patent

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for its 2015 licensed patent application, No. 2887841 entitled, “Cannabis Drug Detection Device”. The Company has been pursuing this original patent application since its filing on April 16, 2015. It should be noted that a notice of allowance from the CIPO does not constitute a grant of patent. The Company will report on future material developments regarding its “Cannabis Drug Detection Device” patent application with CIPO in due course.

Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.

For Full Release: https://www.globenewswire.com/en/news-release/2021/04/19/2212426/0/en/Cannabix-Technologies-Receives-Notice-of-Allowance-for-Cannabis-Drug-Detection-Device-Canadian-Patent.html

April 07, 2021 - Cannabix Technologies to Beta Test Marijuana Breathalyzer with Private Clinic in Northwestern U.S.

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that it will begin beta testing its THC Breath Analyzer (“THCBA”) with a private drug testing clinic located in the Northwestern United States. Cannabix expects to deliver its version 3.0 THCBA prototype to this clinic in the coming weeks to begin a breath testing with select patients. The Company and the clinic have entered into a non-disclosure agreement. The collaborating clinic has a robust drug testing operation and is one of the top drug testing providers to employers within its respective state. The high-volume clinic has a diverse range of patients and focuses on private sector testing for alcohol and illicit drugs. The clinic has extensive experience beta testing with new drug testing technologies. In the recent past, the collaborating clinic was selected to be an early tester of oral swab devices, which have been authorized for use in certain jurisdictions.

Beta-testing of the THCBA prototype will be focused on training the device’s machine learning database, to help determine sensitivity ranges and improving user and administrator experience. Furthermore, this data will help with identifying cross-reactivity of other substances with the study population. The THCBA is a drug screening device for employers and other markets who are seeking a way to quickly, easily and non-invasively test for recent use of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.

Current forms of testing for marijuana use can identify THC ranging from minutes to days prior to actual use, making it difficult to show the difference between the two.  Studies¹ have shown that breath is a better indicator of impairment than saliva and urine because THC is present in breath for a relatively short period of time (1-3 hours); whereas, it is excreted at detectable levels in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window.

(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104…

For Full Release: https://www.globenewswire.com/en/news-release/2021/04/07/2205897/0/en/Cannabix-Technologies-to-Beta-Test-Marijuana-Breathalyzer-with-Private-Clinic-in-Northwestern-U-S.html

Feb. 25, 2021 - Cannabix Technologies Develops Version 3.0 of THC Breath Analyzer Device

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (FRANKFURT: 8CT) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, is pleased to report that it has developed the latest version of the THC Breath Analyzer (“THCBA) prototype and portable system for field use. The new system incorporates a new protective case which houses a sterilization module, smart sample preparation stage and integrated battery charging system.  In addition, engineers have enhanced the handheld device for field use in several ways including revisions to the screen placement, improved breath flow analysis and upgraded microcontroller. New images of the THCBA version 3.0 are included in this press release and available on the Company’s website.

THCBA testing is ongoing and is focused on training the device’s machine learning database, determining sensitivity ranges and improving user and administrator experience. The THCBA has been built to provide easy to understand screen prompts for the positive and negative detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment in breath, and can be administered with limited training. The system provides results in under five minutes.

The THCBA has been targeted for employers and other markets who are seeking a way to quickly, easily and non-invasively test for recent use of THC. Employers everywhere are struggling with the limitations of current drug testing technology in identifying recent use of marijuana that may be causing impairment during work hours and differentiating this from recreational and medical use during nonwork hours/days. The Cannabix device allows for more relevant THC detection from breath allowing employers to create an onsite regiment whereby they can perform pre-access testing for recent use of marijuana before and during work hours, instead of testing for drug use when employees are not at work.

Current forms of testing for marijuana use can identify THC ranging from minutes to days prior to actual use, making it impossible to show the difference between the two.  Studies¹ have shown that breath is a better indicator of impairment than saliva, blood, or urine because THC is present in breath for a relatively short period of time (1-3 hours); whereas, it is excreted at detectable levels in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window.

The Company wants to acknowledge the rapidly changing environment for cannabis use in the U.S. The November election in the U.S. saw the addition of Arizona, Montana, New Jersey, and South Dakota approving recreational marijuana legalization. In February, news agencies have reported that that top Democrats including senators Cory Booker (NJ), Ron Wyden (OR), and Chuck Schumer (NY) are seeking to advance comprehensive cannabis reform legislation in the United States Congress. These kinds of significant developments increase the focus on public safety as cannabis use is legalized in new jurisdictions and emphasizes the importance of the kinds of tools that Cannabix Technologies is developing to support public safety.

(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104…

For Full Release: https://www.globenewswire.com/en/news-release/2021/02/25/2182518/0/en/Cannabix-Technologies-Develops-Version-3-0-of-THC-Breath-Analyzer-Device.html

Jan. 12, 2021 - Cannabix Technologies Granted U.S. Patent - Cannabis Drug Detection Device

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” to the Company. The Company and its patent attorneys have been pursuing this patent application since its filing in 2014. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.

“The intellectual property protection this THC detection patent covers, gives Cannabix a broad foundation to build upon in view of the formidable insights and technical advancements made in the field of molecular gas analysis at atmospheric pressure that we have developed since this patent was initially filed in 2014. Considering the field of breath detection of drugs is in its infancy, this patent is a useful step in our IP protection strategy,” said Dr. Raj Attariwala.

In light of the granting of U.S. patent 14/689434, the Company undertaken a strategic review of its existing patent applications and will re-align its portfolio by canceling its second licence agreement with the University of Florida (UF) in relation to patent application 16/082,220. The Company will continue with its original licence agreement with UF in relation to patent 8,237,118.

As a requirement under the licence agreement between the Company and Cannabix Breathalyzer Inc. (a separate entity) entered into on June 5th, 2014, Company will issue 5 million common shares to Cannabix Breathalyzer Inc. as a final milestone payment, triggered by the grant of patent 14/689434 by the USPTO.

For Full Release: https://www.globenewswire.com/en/news-release/2021/01/12/2157123/0/en/Cannabix-Technologies-Granted-U-S-Patent-Cannabis-Drug-Detection-Device.html

November 23, 2020 - Cannabix Technologies to Beta Test Marijuana Breathalyzer with Occupational Health Clinic in Southern California to Meet Workplace Drug Testing Needs

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that it plans to begin beta testing its version 3.0 THC Breath Analyzer (“THCBA”) in southern California with an occupational health care provider located in Newport Beach. Cannabix expects to deliver its latest version of the THCBA to Alipour Medical Centre early in the new year. Alipour Medical Centre provides drug and alcohol testing services to a number of local employers in the state. The THCBA is an ideal device for employers and other markets who are seeking a way to quickly, easily and non-invasively test for recent use of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment. Cannabix will be seeking additional organizations for beta testing and welcomes interested parties to contact us via our website (cannabixtechnologies.com).

Employers everywhere are struggling with the limitations of current drug testing technology in identifying recent use of marijuana that may be causing impairment during work hours and differentiating this from recreational and medical use during nonwork hours/days.

The Cannabix device allows for more relevant THC detection from breath allowing employers to create an onsite regiment whereby they can perform pre-access testing for recent use of marijuana before and during work hours, instead of testing for drug use when employees are not at work. Cannabix will be beta testing its device in order to continue training the device’s machine learning database and improve user experience through testing feedback. The THCBA has been built to provide easy to understand screen prompts for the positive and negative detection of THC in breath in a portable manner, and can be administered without extensive training.

Current forms of testing for marijuana use can identify THC ranging from minutes to days prior to actual use, making it impossible to show the difference between the two.  Studies¹ have shown that breath is a better indicator of impairment than saliva, blood, or urine because THC is present in breath for a relatively short period of time (1-3 hours); whereas, it is excreted at detectable levels in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window.

Dr. Nima Alipour, CEO of Alipour Medical Corp, stated, “We are very pleased to be using one of the world’s first marijuana breathalyzers in our medical facility. We know first-hand how the legalization of marijuana has affected employers in our state.  As occupational health practitioners based in Orange County, we understand the challenges that employers are facing in providing relevant drug testing for existing and new employees.  We advise corporations on how best to keep their workforce safe; identifying safety issues as they pertain to impairment, while taking into account employee rights in an environment of state legalization. Alipour Medical prides itself on deploying cutting edge technology in our practice and we look forward to helping with research, and ultimately beta testing devices alongside Cannabix Technologies in California.”

Parties interested in working with Cannabix to beta-test its Cannabix Marijuana Breathalyzer are encouraged to contact the Company at info@cannabixtechnologies.com

(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104.

For Full Release: https://www.globenewswire.com/en/news-release/2020/11/23/2131862/0/en/Cannabix-Technologies-to-Beta-Test-Marijuana-Breathalyzer-with-Occupational-Health-Clinic-in-Southern-California-to-Meet-Workplace-Drug-Testing-Needs.html

Oct. 28, 2020 - Cannabix Technologies Receives Notice of Allowance for Cannabis Drug Detection Device U.S. Patent

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its 2015 licensed patent application, No. 14/689434 entitled, “Cannabis Drug Detection Device”. The Company and its patent attorneys have been vigorously pursuing this original patent application since its filing in the spring of 2015. It should be noted that a notice of allowance from the USPTO does not constitute a grant of patent. The Company will report on future material developments regarding its “Cannabis Drug Detection Device” patent application in due course.

Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.

For Full Release: https://www.globenewswire.com/en/news-release/2020/10/28/2115944/0/en/Cannabix-Technologies-Receives-Notice-of-Allowance-for-Cannabis-Drug-Detection-Device-U-S-Patent.html

Oct. 05, 2020 - Cannabix Achieves New Plateau with its FAIMS Marijuana Breathalyzer Technology

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its 2015 licensed patent application, No. 14/689434 entitled, “Cannabis Drug Detection Device”. The Company and its patent attorneys have been vigorously pursuing this original patent application since its filing in the spring of 2015. It should be noted that a notice of allowance from the USPTO does not constitute a grant of patent. The Company will report on future material developments regarding its “Cannabis Drug Detection Device” patent application in due course.

Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.

For Full Release: https://www.globenewswire.com/en/news-release/2020/10/28/2115944/0/en/Cannabix-Technologies-Receives-Notice-of-Allowance-for-Cannabis-Drug-Detection-Device-U-S-Patent.html

August 13, 2020 - Cannabix Technologies Provides Update on THC Breath Analyzer Development and Testing

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that it has been performing user testing with human subjects in Vancouver, BC with its version 2.0 THC Breath Analyzer (“THCBA”). The THCBA device currently provides results in under five minutes. Cannabix has been testing the THCBA device with positive and negative cannabis breath samples with the objective of further training the device’s machine learning database and optimizing components for its upcoming (more robust) version 3.0 device. In recent weeks, Company engineers have also been focusing on device scalability, reducing device production costs, and have tested new thermoplastic soft molded components that would allow for higher durability, and reproducibility. Additional sensors are being incorporated into the device that will integrate more breath sample meta-data and will allow for device usage under a wider range of environmental conditions. Engineers have also developed a technique for sanitization of the device between users, and the GUI for the device has been simplified for administrators.  Many of these improvements have been incorporated into the current device and other improvements are scheduled to be included into a version 3.0 device that will undergo more widespread pilot use. Recent pictures of user testing activity with the THCBA version 2.0 are included in this press release and available on the Company’s website at www.cannabixtechnologies.com.

The user testing procedure includes a baseline breath sample prior to the subject smoking cannabis followed by samples taken after smoking cannabis at multiple time points up to a minimum of 2 hours.  Newly available images show how a subject interacts with the device at various stages of use. The testing process includes a sampling stage, an analysis stage, and the results stage – showing when THC is detected (a positive result) and when THC is not detected (a negative result).

The THCBA incorporates microfluidic sensor technology for the detection of THC from breath. The Company has been developing the THCBA with Dr. Mina Hoorfar at University of British Columbia Okanagan campus (“UBC”) and has an exclusive technology license agreement with UBC. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.

For Full Release:  https://www.globenewswire.com/en/news-release/2020/08/13/2077914/0/en/Cannabix-Technologies-Provides-Update-on-THC-Breath-Analyzer-Development-and-Testing.html

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com  (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For cannabix technologies inc. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated fifteen thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com